Trastuzumab “dttb” – what does that refer to?
It’s not a standard abbreviation you’ll see in most formularies. Most people are referring to the brand‑name drug Herceptin (trastuzumab) or its generic counterparts, sometimes labeled “trastuzumab‑dttb” in certain payer or pharmacy systems to denote a specific formulation or batch. In any case, the pricing landscape is similar across the board, so the numbers below will give you a reasonable ball‑park for the drug itself.
---
1. U.S. Price Snapshot
| Product (formulation) | Typical vial size | Approx. list price (MSI) | Typical infusion cost (incl. pharmacy & infusion center) |
|-----------------------|-------------------|---------------------------|--------------------------------------------------------|
| Herceptin (trastuzumab) | 37.5 mg | $1,200–$1,500 | $1,400–$2,200 |
| Herceptin (trastuzumab) | 150 mg | $3,000–$4,000 | $3,500–$5,000 |
| Generic trastuzumab (e.g., “trastuzumab‑dttb”) | 37.5 mg | $650–$900 | $800–$1,200 |
| Generic trastuzumab | 150 mg | $2,000–$2,800 | $2,500–$3,800 |
Key points
- MSI (Manufacturer’s Suggested Price) is the “sticker price.” Actual reimbursement depends on contracts with insurers, Medicare/Medicaid, pharmacy benefit managers, and patient assistance programs.
- DTTB: If your pharmacy or insurer uses a code like “trastuzumab‑dttb,” they’re usually referencing a specific vial size or a particular manufacturer’s formulation. The price remains in the range above.
- Discounts: Many insurers negotiate a discounted acquisition cost (DAC) that can bring the effective cost to 60‑80% of MSRP. Patient assistance programs can reduce the net price further for qualifying patients.
---
2. Global Perspective (a quick look)
| Country | Approx. cost per 150 mg vial | Notes |
|---------|------------------------------|-------|
| Canada | CAD 1,200–1,400 (~$900–$1,100 USD) | Public plans often cover most of the cost; drug discount programs available. |
| UK (NHS) | £1,500–£1,800 (~$2,100–$2,500 USD) | NHS bulk purchasing keeps costs lower than private payers. |
| Australia | AUD 1,000–1,200 (~$650–$780 USD) | Subsidised through PBS (Pharmaceutical Benefits Scheme). |
| India | INR 45,000–50,000 (~$600–$700 USD) | Generics available at much lower prices; brand prices are high. |
Prices are approximate and can fluctuate based on local market conditions and supply contracts.
---
3. Typical Treatment Course Costs
A standard trastuzumab regimen for HER‑2‑positive breast cancer (e.g., 8 mg/kg IV every 3 weeks for 1 year) involves roughly 17–18 infusions:
- Brand Herceptin: ~$50,000–$70,000 USD per year (MSI) – but many payers reimburse around 60–70% of that.
- Generic: ~$25,000–$35,000 USD per year – again, actual patient out‑of‑pocket costs can be lower after insurance coverage and patient assistance programs.
---
4. How to Get the Exact Price for Your Situation
1. Ask your pharmacy: They’ll have the specific “dttb” SKU and can give you the current acquisition cost (the price they actually pay the manufacturer, not the MSI).
2. Check your insurance: The pharmacy benefits manager (PBM) contract will dictate your copay or coinsurance amount.
3. Look for patient assistance programs: Genentech, Amgen, and several non‑profits offer help for patients who meet income thresholds.
4. Ask your oncologist: They can often guide you toward the cheapest equivalent formulation or a clinical trial offering the drug at no cost.
---
Bottom line
- Trastuzumab “dttb” is essentially the same drug as Herceptin, but it may be a generic or a specific vial size.
- The list price for a 150 mg vial is usually between $3,000 and $4,000 in the U.S., while generics can be $2,000–$3,000.
- Actual out‑of‑pocket costs can be 30‑70% lower, depending on your insurance and any discount programs.
If you can share your country, payer type, or the exact vial size you’re looking at, I can give you a more tailored estimate.